Results support advancement into phase 2 trials
Results support advancement into phase 2 trials
Agreement enables procurement in over 50 countries
Results support combination strategy for influenza vaccines
Global trials assess migraine prevention potential
Recommendation supports second-line combination option
Positive opinion supports EU marketing authorisation
Regimen update recommended across all indications
New Frankfurt site to boost long-term supply
New company to advance first‑in‑class treatment
Phase 2 development underway as DARE2 trial begins
Partnership expands Bespak’s intranasal dry powder capabilities
New long‑term results reinforce efficacy across AD and PN
New option offers acute treatment for adults with migraine
Final analysis shows durable outcomes in MF and SS
First long‑acting therapy targeting root cause of ATTR‑CM